Trial Profile
An Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate Drug-drug Interaction Following Oral Administration of Gemigliptin and Dapagliflozin or Empagliflozin in Healthy Adult Volunteers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 May 2020
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Empagliflozin (Primary) ; Gemigliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 28 Jun 2018 New trial record